Therapeutic vaccination in HIV infection
Mina John
+ Author Affiliations
- Author Affiliations
Department of Clinical Immunology
Royal Perth Hospital
Wellington Street
Perth, WA 6000, Australia
Tel: +61 8 9224 2899
Fax: +61 8 9224 2920
Email: M.John@iiid.com.au
Microbiology Australia 35(2) 93-95 https://doi.org/10.1071/MA14028
Published: 7 May 2014
Abstract
The concept of using a vaccine to induce or enhance HIV-specific immune responses in those with established HIV infection has been through alternating waves of enthusiasm and skepticism over the past three decades of the HIV epidemic. The earliest therapeutic vaccination trials were conducted in subjects with uncontrolled viremia or suboptimal therapy and the highly activated and dysfunctional immune environment of such individuals would significantly impede the efficacy of any immunostimulatory approaches. Contemporary antiretroviral treatment assures potent and sustained inhibition of HIV replication, reduces immune activation and restores a variety of specific immune functions. This provides the context for a renewed level of scientific interest in the possibility of inducing HIV-specific immunity that could clear virally infected cells, retain long lived memory, and help reduce latent reservoirs of HIV that cannot be eliminated by current drugs or intensification strategies.
References
[1] Rerks-Ngarm, S. et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220.| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXhsFWhsb%2FO&md5=975d5fe43a25c7b782c45db3b6e74b5cCAS | 19843557PubMed |
[2] Tubiana, R. et al. (2005) Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter Study (ANRS094). Vaccine 23, 4292–4301.
| Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter Study (ANRS094).Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXlvFOjsbs%3D&md5=38f8a2a57b1d2191880a2784b9cc6877CAS | 15927325PubMed |
[3] Kinloch-de Loes, S. et al. (2005) Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 192, 607–617.
| Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXpvVSqs7w%3D&md5=ea10d7c74a5bdd713a124fc24a881901CAS | 16028129PubMed |
[4] Autran, B. et al. (2008) Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22, 1313–1322.
| Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXns1Oqt7c%3D&md5=bc9eb7cd36d5218456f4c2911be56272CAS | 18580611PubMed |
[5] French, M.A. et al. (2010) Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ’high-affinity’ FcgammaRIIa genotype. AIDS 24, 1983–1990.
| Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ’high-affinity’ FcgammaRIIa genotype.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXps1Wnu7w%3D&md5=224410477dc7568b6fa8dc72cfb6bf2cCAS | 20634666PubMed |
[6] Dorrell, L. et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25, 3277–3283.
| Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXjvFGrtbo%3D&md5=fb6f1ae7f9b08b8cf0c7ffa4ba55416cCAS | 17257714PubMed |
[7] Schooley, R.T. et al. (2010) AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J. Infect. Dis. 202, 705–716.
| AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXhtFKjsr%2FJ&md5=f43d5f469ade670e6fdbf28185e4e310CAS | 20662716PubMed |
[8] Duerr, A. et al. (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206, 258–266.
| Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).Crossref | GoogleScholarGoogle Scholar | 22561365PubMed |
[9] Gray, G. et al. (2010) Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr. Opin. HIV AIDS , 357–361.
| Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.Crossref | GoogleScholarGoogle Scholar | 20978374PubMed |
[10] Kraynyak, K.A. et al. (2010) Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 28, 1942–1951.
| Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXisFKisrk%3D&md5=f352d16c9481f1e68d8eb1790250ebdeCAS | 20188250PubMed |
[11] Rosenberg, E.S. et al. (2010) Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS ONE 5, e10555.
| Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.Crossref | GoogleScholarGoogle Scholar | 20479938PubMed |
[12] Harrer, T. et al. (2013) Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine , .
| Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.Crossref | GoogleScholarGoogle Scholar | 24144472PubMed |
[13] Miller, E.A. et al. (2012) Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J. Aacquir. Immune Defic. Syndr. 61, 535–544.
| Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhslGjs7vI&md5=927b4f00fdf97550730b6a9844d0b44fCAS |
[14] Granelli-Piperno, A. et al. (2006) HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J. Immunol. 176, 991–998.
| 1:CAS:528:DC%2BD28Xht1Ghsg%3D%3D&md5=a98e7e651d03b9c902376fd0231d89b5CAS | 16393985PubMed |
[15] Kundu, S.K. et al. (1998) A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 14, 551–560.
| A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1c3lt1ersQ%3D%3D&md5=ad98f4132ad12a59466ac6bcec4ab4c8CAS | 9591709PubMed |
[16] Ide, F. et al. (2006) Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J. Med. Virol. 78, 711–718.
| Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28Xlt1Kjs70%3D&md5=1d5d8def9c7e3f5d3543dd166fea045cCAS | 16628588PubMed |
[17] García, F. et al. (2005) Immunotherapy and therapeutic vaccines in HIV infection. Enferm. Infecc. Microbiol. Clin. 23, 95–104.
| Immunotherapy and therapeutic vaccines in HIV infection.Crossref | GoogleScholarGoogle Scholar |
[18] Garcia F.
[19] Routy, J.P. et al. (2010) Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1infected patients receiving antiretroviral therapy. Clin. Immunol. 134, 140–147.
| Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1infected patients receiving antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXjslClsA%3D%3D&md5=3f8cc98ce27951e628660f83e2f9b5a9CAS | 19889582PubMed |
[20] Routy, J.P. and Nicolette, C. (2010) Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2, 467–476.
| Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXovFeqtrc%3D&md5=c3a836a2551c46b2a75269e82387db3cCAS | 20636001PubMed |
[21] Van Gulck, E. et al. (2012) mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 26, F1–F12.
| mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XitVSltL0%3D&md5=536dccda1bcaacfc1c543e2e44615e7aCAS | 22156965PubMed |
